Skip to main content
Erschienen in: Current Treatment Options in Oncology 6/2022

08.04.2022 | Skin Cancer (T Ito, Section Editor)

Dermatofibrosarcoma Protuberans in Children

verfasst von: Aseel Sleiwah, MBChB MRCS MSc, Thomas C. Wright, MBChB MSc FRCS (Plast), Thomas Chapman, BSc, MBChB, FRCS (Plast), Adam Dangoor, BM, BS, MRCP, MD, Francesca Maggiani, MBBS MD, Rachel Clancy, MBChB, FRCS Plast

Erschienen in: Current Treatment Options in Oncology | Ausgabe 6/2022

Einloggen, um Zugang zu erhalten

Opinion statement

Paediatric dermatofibrosarcoma protuberans (DFSP) is a rare soft tissue malignant tumour which displays aggressive local behaviour and has low metastatic potential. The diagnosis is often delayed as DFSP is usually mistaken for other skin conditions, particularly in the early stages of disease. DFSP tends to follow an indolent course after the initial presentation with what is often described as a “rubbery lump”. As the disease progresses, the lump tends to enlarge, change colour, and exhibit a more nodular consistency. In rare cases, DFSP can present as an ulcerated exophytic lesion or a depressed area of skin, making diagnosis even more challenging. A high index of suspicion is warranted for early diagnosis, and referral to a specialist unit with expertise in both oncologic resection and reconstruction. DFSP tumours arise from the dermis and grow with finger-like projections. Therefore, in cosmetically sensitive or functionally important locations, an excision and analysis technique that assesses all excision margins is the gold standard of care. Slow Mohs technique performed with en bloc excision is a well-tolerated option for oncologic resection of the tumour. Mohs technique can also be considered but can be challenging in children for reasons explained below. As an alternative, depending on the anatomical location, tumours can be excised with a wide local excision. While an excision technique that incorporates the deep fascia with a 3-cm peripheral margin is acceptable in adults, planning of the excision margin in children should involve consideration of preoperative imaging with MRI, site of the tumour, age, and physical built of the child. Patients should be offered all treatment options considering the local outcomes, available expertise, and cost. A multidisciplinary approach and good communication between team members is crucial. Close collaboration with a pathologist who is familiar with sectioning technique that allows margin control is of paramount importance. Soft tissue reconstruction should be performed immediately after oncologic clearance, although a staged approach may be required. Adjuvant radiotherapy should be avoided in children due to the long-term risk of secondary malignancies and potential for growth disruption.
Literatur
6.
Zurück zum Zitat • Sleiwah A, Psomadakis C, Craythorne E, Stefanato CM, Rickaby W, Robson A, Mellerio JE, Greig A. Dermatofibrosarcoma protuberans (DFSP) in children: a combined multidisciplinary approach. Pediatr Dermatol. 2021;38(1):233–6. https://doi.org/10.1111/pde.14425 This reference is of importance as it reports excision of paediatric DFSP utilising slow Mohs under general anaesthesia and discusses advantages of slow Mohs over Mohs surgery.CrossRefPubMed • Sleiwah A, Psomadakis C, Craythorne E, Stefanato CM, Rickaby W, Robson A, Mellerio JE, Greig A. Dermatofibrosarcoma protuberans (DFSP) in children: a combined multidisciplinary approach. Pediatr Dermatol. 2021;38(1):233–6. https://​doi.​org/​10.​1111/​pde.​14425 This reference is of importance as it reports excision of paediatric DFSP utilising slow Mohs under general anaesthesia and discusses advantages of slow Mohs over Mohs surgery.CrossRefPubMed
9.
Zurück zum Zitat Hoffmann, Erich Dr. phil.. “I. Über das knollentreibende Fibrosarkom der Haut (Dermatofibrosarkoma protuberans).” Dermatology 43:1–28. Hoffmann, Erich Dr. phil.. “I. Über das knollentreibende Fibrosarkom der Haut (Dermatofibrosarkoma protuberans).” Dermatology 43:1–28.
10.
Zurück zum Zitat Darier J. Dermatofibromes progressifs et recidivants ou fibrosarcomes de la peau. Ann Dermatol Venereol. 1924;5:545–62. Darier J. Dermatofibromes progressifs et recidivants ou fibrosarcomes de la peau. Ann Dermatol Venereol. 1924;5:545–62.
15.
Zurück zum Zitat Kim GK. Status report on the management of dermatofibrosarcoma protuberans: is there a viable role for the use of imatinib mesylate? In which cases may it be therapeutically helpful and in which cases not? J Clin Aesthet Dermatol. 2011;4(3):17–26.PubMedPubMedCentral Kim GK. Status report on the management of dermatofibrosarcoma protuberans: is there a viable role for the use of imatinib mesylate? In which cases may it be therapeutically helpful and in which cases not? J Clin Aesthet Dermatol. 2011;4(3):17–26.PubMedPubMedCentral
16.
Zurück zum Zitat Bowne WB, Antonescu CR, Leung DH, Katz SC, Hawkins WG, Woodruff JM, Brennan MF, Lewis JJ. Dermatofibrosarcoma protuberans: a clinicopathologic analysis of patients treated and followed at a single institution. Cancer. 2000;88(12):2711–20.CrossRef Bowne WB, Antonescu CR, Leung DH, Katz SC, Hawkins WG, Woodruff JM, Brennan MF, Lewis JJ. Dermatofibrosarcoma protuberans: a clinicopathologic analysis of patients treated and followed at a single institution. Cancer. 2000;88(12):2711–20.CrossRef
24.
27.
Zurück zum Zitat Kutzner H, Mentzel T, Palmedo G, Hantschke M, Rütten A, Paredes BE, Schärer L, Guillen CS, Requena L. Plaque-like CD34-positive dermal fibroma (“medallion-like dermal dendrocyte hamartoma”): clinicopathologic, immunohistochemical, and molecular analysis of 5 cases emphasizing its distinction from superficial, plaque-like dermatofibrosarcoma protuberans. Am J Surg Pathol. 2010;34(2):190–201. https://doi.org/10.1097/PAS.0b013e3181c7cf11.CrossRefPubMed Kutzner H, Mentzel T, Palmedo G, Hantschke M, Rütten A, Paredes BE, Schärer L, Guillen CS, Requena L. Plaque-like CD34-positive dermal fibroma (“medallion-like dermal dendrocyte hamartoma”): clinicopathologic, immunohistochemical, and molecular analysis of 5 cases emphasizing its distinction from superficial, plaque-like dermatofibrosarcoma protuberans. Am J Surg Pathol. 2010;34(2):190–201. https://​doi.​org/​10.​1097/​PAS.​0b013e3181c7cf11​.CrossRefPubMed
32.
Zurück zum Zitat Wrotnowski U, Cooper PH, Shmookler BM. Fibrosarcomatous change in dermatofibrosarcoma protuberans. Am J Surg Pathol. 1988;12(4):287–93.CrossRef Wrotnowski U, Cooper PH, Shmookler BM. Fibrosarcomatous change in dermatofibrosarcoma protuberans. Am J Surg Pathol. 1988;12(4):287–93.CrossRef
34.
Zurück zum Zitat NCCN clinical practice guidelines in oncology: dermatofibrosarcoma protuberans, National comprehensive cancer network. 2021 NCCN clinical practice guidelines in oncology: dermatofibrosarcoma protuberans, National comprehensive cancer network. 2021
36.
Zurück zum Zitat Ratner D, Thomas CO, Johnson TM, Sondak VK, Hamilton TA, Nelson BR, et al. Mohs micrographic surgery for the treatment of dermatofibrosarcoma protuberans. Results of a multi-institutional series with an analysis of the extent of microscopic spread. J Am Acad Dermatol. 1997;37:600–13.CrossRef Ratner D, Thomas CO, Johnson TM, Sondak VK, Hamilton TA, Nelson BR, et al. Mohs micrographic surgery for the treatment of dermatofibrosarcoma protuberans. Results of a multi-institutional series with an analysis of the extent of microscopic spread. J Am Acad Dermatol. 1997;37:600–13.CrossRef
37.
Zurück zum Zitat Foroozan M, Sei JF, Amini M, Beauchet A, Saiag P. Efficacy of Mohs micrographic surgery for the treatment of dermatofibrosarcoma protuberans: systematic review. Arch Dermatol. 2012;148(9):1055–63.CrossRef Foroozan M, Sei JF, Amini M, Beauchet A, Saiag P. Efficacy of Mohs micrographic surgery for the treatment of dermatofibrosarcoma protuberans: systematic review. Arch Dermatol. 2012;148(9):1055–63.CrossRef
38.
Zurück zum Zitat Matin RN, Acland KM, Williams HC. Is Mohs micrographic surgery more effective than wide local excision for treatment of dermatofibrosarcoma protuberans in reducing risk of local recurrence? A critically appraised topic. Br J Dermatol. 2012;167(1):6–9.CrossRef Matin RN, Acland KM, Williams HC. Is Mohs micrographic surgery more effective than wide local excision for treatment of dermatofibrosarcoma protuberans in reducing risk of local recurrence? A critically appraised topic. Br J Dermatol. 2012;167(1):6–9.CrossRef
40.
Zurück zum Zitat Paoli J, Cogrel O, van der Geer S, Krekels G, de Leeuw J, Moehrle M, Ostertag J, Buceta LR, Sheth N, Läuchli S. ESMS position document on the use of Mohs micrographic surgery and other micrographic surgery techniques In Europe. Paoli J, Cogrel O, van der Geer S, Krekels G, de Leeuw J, Moehrle M, Ostertag J, Buceta LR, Sheth N, Läuchli S. ESMS position document on the use of Mohs micrographic surgery and other micrographic surgery techniques In Europe.
42.
Zurück zum Zitat •• Zargham H, Khachemoune A. Systematic review of Mohs micrographic surgery in children: identifying challenges and practical considerations for successful application. J Am Acad Dermatol. 2021;85(1):152–61. https://doi.org/10.1016/j.jaad.2020.09.052 This reference is of outstanding importance as it discusses the challenges of performing Mohs micrographic surgery in children.CrossRefPubMed •• Zargham H, Khachemoune A. Systematic review of Mohs micrographic surgery in children: identifying challenges and practical considerations for successful application. J Am Acad Dermatol. 2021;85(1):152–61. https://​doi.​org/​10.​1016/​j.​jaad.​2020.​09.​052 This reference is of outstanding importance as it discusses the challenges of performing Mohs micrographic surgery in children.CrossRefPubMed
43.
Zurück zum Zitat • Brough KR, Youssef MJ, Winchester DS, Baum CL, Sharaf BA, Roenigk RK. Mohs micrographic surgery for dermatofibrosarcoma protuberans in 7 patients aged 10 years and younger. J Am Acad Dermatol. 2021 Jun 29:S0190-9622(21)02001-6. https://doi.org/10.1016/j.jaad.2021.06.856. This reference is of importance as it reports on case series of paediatric patients managed utilising Mohs micrographic surgery. • Brough KR, Youssef MJ, Winchester DS, Baum CL, Sharaf BA, Roenigk RK. Mohs micrographic surgery for dermatofibrosarcoma protuberans in 7 patients aged 10 years and younger. J Am Acad Dermatol. 2021 Jun 29:S0190-9622(21)02001-6. https://​doi.​org/​10.​1016/​j.​jaad.​2021.​06.​856. This reference is of importance as it reports on case series of paediatric patients managed utilising Mohs micrographic surgery.
44.
Zurück zum Zitat Gattoni M, Tiberio R, Angeli L, Bornacina G, Boggio P, Annali G, Giacalone A, Cristina S, Leigheb G. Dermatofibrosarcome de Darier-Ferrand: traitement par la technique chirurgicale de Tübingen (31 cas) [Dermatofibrosarcoma protuberans: surgical treatment using the Tübingen technique (31 cases)]. Ann Dermatol Venereol. 2007;134(1):31–4. French. https://doi.org/10.1016/s0151-9638(07)88985-x. Gattoni M, Tiberio R, Angeli L, Bornacina G, Boggio P, Annali G, Giacalone A, Cristina S, Leigheb G. Dermatofibrosarcome de Darier-Ferrand: traitement par la technique chirurgicale de Tübingen (31 cas) [Dermatofibrosarcoma protuberans: surgical treatment using the Tübingen technique (31 cases)]. Ann Dermatol Venereol. 2007;134(1):31–4. French. https://​doi.​org/​10.​1016/​s0151-9638(07)88985-x.
46.
Zurück zum Zitat •• Durack A, Gran S, Gardiner MD, Jain A, Craythorne E, Proby CM, Marsden J, Harwood CA, Matin RN, DFSP Collaborators. A 10-year review of surgical management of dermatofibrosarcoma protuberans. Br J Dermatol. 2021;184(4):731–9. https://doi.org/10.1111/bjd.19346 This reference is of outstanding importance as it reports on a nationwide study that examines WLE versus micrographic surgery. It shows that the recurrence rate following WLE is very small in their cohort compared to other studies.CrossRefPubMed •• Durack A, Gran S, Gardiner MD, Jain A, Craythorne E, Proby CM, Marsden J, Harwood CA, Matin RN, DFSP Collaborators. A 10-year review of surgical management of dermatofibrosarcoma protuberans. Br J Dermatol. 2021;184(4):731–9. https://​doi.​org/​10.​1111/​bjd.​19346 This reference is of outstanding importance as it reports on a nationwide study that examines WLE versus micrographic surgery. It shows that the recurrence rate following WLE is very small in their cohort compared to other studies.CrossRefPubMed
50.
Zurück zum Zitat Kérob D, Porcher R, Vérola O, Dalle S, Maubec E, Aubin F, D'Incan M, Bodokh I, Boulinguez S, Madelaine-Chambrin I, Mathieu-Boue A, Servant JM, de Kerviler E, Janin A, Calvo F, Pedeutour F, Lebbe C. Imatinib mesylate as a preoperative therapy in dermatofibrosarcoma: results of a multicenter phase II study on 25 patients. Clin Cancer Res. 2010;16(12):3288–95. https://doi.org/10.1158/1078-0432.CCR-09-3401.CrossRefPubMed Kérob D, Porcher R, Vérola O, Dalle S, Maubec E, Aubin F, D'Incan M, Bodokh I, Boulinguez S, Madelaine-Chambrin I, Mathieu-Boue A, Servant JM, de Kerviler E, Janin A, Calvo F, Pedeutour F, Lebbe C. Imatinib mesylate as a preoperative therapy in dermatofibrosarcoma: results of a multicenter phase II study on 25 patients. Clin Cancer Res. 2010;16(12):3288–95. https://​doi.​org/​10.​1158/​1078-0432.​CCR-09-3401.CrossRefPubMed
51.
Zurück zum Zitat Sjöblom T, Shimizu A, O'Brien KP, Pietras K, Dal Cin P, Buchdunger E, Dumanski JP, Ostman A, Heldin CH. Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res. 2001;61(15):5778–83.PubMed Sjöblom T, Shimizu A, O'Brien KP, Pietras K, Dal Cin P, Buchdunger E, Dumanski JP, Ostman A, Heldin CH. Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res. 2001;61(15):5778–83.PubMed
53.
Zurück zum Zitat McArthur GA, Demetri GD, van Oosterom A, Heinrich MC, Debiec-Rychter M, Corless CL, Nikolova Z, Dimitrijevic S, Fletcher JA. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J Clin Oncol. 2005;23(4):866–73. https://doi.org/10.1200/JCO.2005.07.088.CrossRefPubMed McArthur GA, Demetri GD, van Oosterom A, Heinrich MC, Debiec-Rychter M, Corless CL, Nikolova Z, Dimitrijevic S, Fletcher JA. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J Clin Oncol. 2005;23(4):866–73. https://​doi.​org/​10.​1200/​JCO.​2005.​07.​088.CrossRefPubMed
61.
Zurück zum Zitat •• David MP, Funderburg A, Selig JP, Brown R, Caliskan PM, Cove L, Dicker G, Hoffman L, Horne T, Gardner JM. Perspectives of patients with dermatofibrosarcoma protuberans on diagnostic delays, surgical outcomes, and nonprotuberance. JAMA Netw Open. 2019;2(8):e1910413. https://doi.org/10.1001/jamanetworkopen.2019.10413. This reference is of importance because it studies patient prospective on DFSP. •• David MP, Funderburg A, Selig JP, Brown R, Caliskan PM, Cove L, Dicker G, Hoffman L, Horne T, Gardner JM. Perspectives of patients with dermatofibrosarcoma protuberans on diagnostic delays, surgical outcomes, and nonprotuberance. JAMA Netw Open. 2019;2(8):e1910413. https://​doi.​org/​10.​1001/​jamanetworkopen.​2019.​10413. This reference is of importance because it studies patient prospective on DFSP.
Metadaten
Titel
Dermatofibrosarcoma Protuberans in Children
verfasst von
Aseel Sleiwah, MBChB MRCS MSc
Thomas C. Wright, MBChB MSc FRCS (Plast)
Thomas Chapman, BSc, MBChB, FRCS (Plast)
Adam Dangoor, BM, BS, MRCP, MD
Francesca Maggiani, MBBS MD
Rachel Clancy, MBChB, FRCS Plast
Publikationsdatum
08.04.2022
Verlag
Springer US
Erschienen in
Current Treatment Options in Oncology / Ausgabe 6/2022
Print ISSN: 1527-2729
Elektronische ISSN: 1534-6277
DOI
https://doi.org/10.1007/s11864-022-00979-9

Weitere Artikel der Ausgabe 6/2022

Current Treatment Options in Oncology 6/2022 Zur Ausgabe

Palliative and Supportive Care (J Hardy, Section Editor)

Do Patients Benefit from a Trial of Corticosteroids at the End of Life?

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.